Celltrion's Herceptin Biosimilar One Step Closer To US FDA Approval
Following Oncologic Drugs Advisory Committee's recommendation for Mylan and Biocon's trastuzumab biosimilar, Celltrion and Teva's CT-P6 appear to be one of the next one in, but given the expiry of Herceptin patent in the US and other late stage trastuzumab biosimilar candidates, it could be anybody's game to launch their products first.
You may also be interested in...
Mylan's Herceptin biosimilar faces questions on off-label use and manufacturing, while Amgen's Avastin biosimilar could be template for other products.
After launching its biosimilar infliximab Inflectra in the US late last year, Celltrion is targeting a leading position in oncology in the US with its biosimilar rituximab emerging as the first to be accepted for review by the US FDA.
Celltrion's version of Roche’s MabThera (rituximab), Truxima, has become the first biosimilar anticancer to win marketing authorization in Europe.